Designing drugs for the treatment of female sexual dysfunction
Drug Discov Today 12(17-18):10 (2007) PMID 17826689
Dysfunction of female sexual desire, arousal, or orgasm affects approximately 30% of women. Early attempts to treat female sexual dysfunction arose out of programs developed for male erectile dysfunction and have proven largely unsuccessful. A new wave of targets is now being pursued; many of these targets are postulated to modulate central pathways. Classical neurotransmitter systems, such as dopamine and serotonin, as well as the neuropeptide melanocortin, are receiving the most attention. Early clinical data look promising; however, clinical trial methodology in female sexual dysfunction is not well developed and only further testing will determine whether these treatments meet regulatory hurdles and satisfy patient need.
DOI: 10.1016/j.drudis.2007.07.007
Version: za2963e q8za4 q8zba q8zce q8zda q8ze6 q8zfe q8zgb